IMC Chicago LLC bought a new position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 22,406 shares of the exchange traded fund's stock, valued at approximately $1,080,000. IMC Chicago LLC owned 2.02% of ProShares Ultra Nasdaq Biotechnology as of its most recent filing with the SEC.
Separately, Crowley Wealth Management Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth approximately $51,000.
ProShares Ultra Nasdaq Biotechnology Trading Down 0.6%
Shares of BIB stock traded down $0.30 on Monday, reaching $47.07. 4,210 shares of the company's stock were exchanged, compared to its average volume of 11,502. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $33.78 and a 52 week high of $69.56. The stock has a market capitalization of $51.78 million, a PE ratio of 20.68 and a beta of 1.63. The company's fifty day simple moving average is $43.74 and its 200 day simple moving average is $49.71.
ProShares Ultra Nasdaq Biotechnology Cuts Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Wednesday, March 26th were paid a dividend of $0.1309 per share. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date of this dividend was Wednesday, March 26th.
About ProShares Ultra Nasdaq Biotechnology
(
Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
